Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05424003 · ClinicalTrials.gov registry record · Phase 2
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
A Phase 2 study of NAFLD, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05424003 is a Phase 2 study of NAFLD that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 50 participants, below the 163-participant average among 26 other NAFLD trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05424003, a Phase 2 study of NAFLD, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic Resonance Imaging (MRI) and laboratory results.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide Pen Injector
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-02-22 |
| Est. Completion | 2026-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05424003
The ClinicalTrials.gov registry entry for NCT05424003 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 163-participant average among 26 other NAFLD trials with a reported enrollment target (69% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NAFLD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05424003 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT05424003 about?
NCT05424003 is a clinical study titled "Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant". In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic F...
What is the current status of trial NCT05424003?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-02-22. Estimated completion is 2026-02.
What conditions does trial NCT05424003 study?
This clinical trial studies the following conditions: NAFLD.
What interventions are being tested in trial NCT05424003?
The interventions under investigation include: Placebo (DRUG), Semaglutide Pen Injector (DRUG).
Who is sponsoring clinical trial NCT05424003?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05424003 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NAFLD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Digoxin In NASH (CODIN)
RECRUITING · Phase 2
-
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
COMPLETED · Phase 2
-
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.